56. Behcet disease Clinical trials / Disease details
Clinical trials : 76 / Drugs : 110 - (DrugBank : 32) / Drug target genes : 36 - Drug target pathways : 116
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00167583 (ClinicalTrials.gov) | November 2004 | 9/9/2005 | Interferon-alpha2a Versus Cyclosporin A for Severe Ocular Behcet's Disease (INCYTOB) | Phase III Study of Recombinant Human Interferon-alpha2a Versus Cyclosporin A for the Treatment of Ocular Behcet's Disease - a National,Randomised, Single-masked Controlled Trial (INCYTOB) | Behcet's Disease;Panuveitis;Posterior Uveitis;Retinal Vasculitis | Drug: Cyclosporin A;Drug: Interferon-alpha2a | University Hospital Tuebingen | NULL | Completed | 18 Years | 75 Years | All | 37 | Phase 3 | Germany |